REMAP-CAP is an embedded platform trial in Europe, Australia,and New Zealand. The trial uses response adaptive randomization based on patient strata for multifactorial treatment regimens. The trial aims to identify the best way to treat patients with different baseline status. While efficiently learning which treatments are the most effective it is already implementing these regimens throughout these continents. This platform trial presents an incredibly efficient learning health care system. A goal of the trial is to have a clinical trial infrastructure immediately ready to react to a pandemic outbreak and immediately investigate therapies for the pandemic.